Proliferation centers in chronic lymphocytic leukemia: correlation with cytogenetic and clinicobiological features in consecutive patients analyzed on tissue microarrays
Maria Ciccone(Arcispedale Sant'Anna), Stefano Pileri(European Institute of Oncology), Attilio Olivieri(Ospedali Riuniti di Ancona), Elena Saccenti(University of Ferrara), Francesco Cavazzini(Arcispedale Sant'Anna), Daniela Capello(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Gian Matteo Rigolin, Immacolata Attolico(Ospedale San Carlo), Pier Paolo Piccaluga(Istituto di Ematologia di Bologna), Maura Brugiatelli(Azienda Ospedaliera Ospedali Riuniti Papardo Piemonte), Olga Sofritti(University of Ferrara), Caterina Stelitano(University of Reggio Calabria), Lara Rizzotto, Elena Sabattini(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Antonio Cuneo(Arcispedale Sant'Anna), Simona Righi(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Giuseppe Fioritoni, Massimo Negrini(University of Ferrara), Pier Luigi Zinzani(Istituto di Ematologia di Bologna), Simona Falorio(Azienda USL di Pescara), Claudio Agostinelli, Maria Teresa Sista(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola)
Cited by 69
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Voriconazole Compared with Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Neutropenia and Persistent Fever
|New England Journal of Medicine|2002|986
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
|The Lancet Haematology|2020|553
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523